Novel Electrochemiluminescent
Immunosensor Using Dual
Amplified Signals from a CoFe Prussian Blue Analogue and Au Nanoparticle
for the Detection of Lp-PLA2
posted on 2023-07-11, 15:06authored byLixin Wang, Yuhong Liu, Jilin Yan, Huiling Li, Yifeng Tu
Coronary heart disease (CHD) poses an important threat
to human
health, and its pathogenesis is the formation of atheromatous plaques
in coronary ventricles. Compared to other biomarkers, lipoprotein-associated
phospholipase A2 (Lp-PLA2), which is involved in multiple processes
of atherosclerosis, is a noticeable inflammatory biomarker related
to CHD. Herein, using a multifunctional nanocomposite containing a
CoFe Prussian blue analogue (PBA) and Au nanoparticles (AuNPs) (AuNPs@CoFe
PBA) as a sensing substrate, an electrochemiluminescent (ECL) immunosensor
was developed for the highly sensitive detection of Lp-PLA2. Benefiting
from the synergistic effect of the PBA and AuNPs, the nanocomposite
exhibits excellent peroxidase-like activity and can catalyze the luminol–ECL
reaction, amplifying the ECL signal by ∼29-fold. Meanwhile,
the enlarged specific surface area of the nanocomposite and the presence
of abundant AuNPs allow the immobilization of more antibody proteins,
thereby improving the sensing response of the immunosensor. When the
target Lp-PLA2 is captured by the antibody on the sensor surface,
the sensor emits a reduced ECL signal because of the increased mass
and electron transfer resistance due to the formation of the immune
complex. Under optimized conditions, the constructed ECL immunosensor
exhibits a broad linear range from 1 to 2200 ng/mL and a low detection
limit of 0.21 ng/mL. Additionally, the ECL immunosensor exhibits high
specificity, stability, and reproducibility. This work provides a
new approach to diagnose CHD and broadened the application of the
PBA in the field of ECL sensors.